Literature DB >> 14766125

Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation?

Sabine L A Plasschaert1, Willem A Kamps, Edo Vellenga, Elisabeth G E de Vries, Eveline S J M de Bont.   

Abstract

Acute lymphoblastic leukaemia (ALL) is a disease diagnosed in children as well as adults. Progress in the treatment of ALL has led to better survival rates, however, children have benefited more from improved treatment modalities than adults. Recent evidence has underscored that the difference in characteristics and biology of adult versus childhood ALL might be the result of a different origin. According to the two-hit paradigm of Knudson, to develop cancer two genetic events are necessary. It has been suggested, that in childhood ALL the first genetic event happens in the more mature lymphoid committed progenitor cells, whereas in adult ALL the first hit occurs in multipotent stem cells. This review compares patient characteristics, the extent of the disease, leukaemic cell characteristics and treatment between childhood and adult ALL. This is discussed in relation to the hypothesis that the maturation stage of the cells, from which the leukaemia arises, is responsible for the differential behaviour of adult and childhood ALL.

Entities:  

Mesh:

Year:  2004        PMID: 14766125     DOI: 10.1016/S0305-7372(03)00140-3

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  16 in total

Review 1.  Topics in pediatric leukemia--acute lymphoblastic leukemia.

Authors:  Samuel D Esparza; Kathleen M Sakamoto
Journal:  MedGenMed       Date:  2005-03-07

Review 2.  Approaches to treatment for acute lymphoblastic leukemia in adolescents and young adults.

Authors:  Ryan Mattison; Wendy Stock
Journal:  Curr Hematol Malig Rep       Date:  2008-07       Impact factor: 3.952

3.  The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL.

Authors:  David T Teachey; Dana A Obzut; Jonathan Cooperman; Junjie Fang; Martin Carroll; John K Choi; Peter J Houghton; Valerie I Brown; Stephan A Grupp
Journal:  Blood       Date:  2005-09-29       Impact factor: 22.113

Review 4.  Targeting PI3K/AKT/mTOR network for treatment of leukemia.

Authors:  Jessika Bertacchini; Nazanin Heidari; Laura Mediani; Silvano Capitani; Mohammad Shahjahani; Ahmad Ahmadzadeh; Najmaldin Saki
Journal:  Cell Mol Life Sci       Date:  2015-02-25       Impact factor: 9.261

5.  Oxidative Stress in Tunisian Patients With Acute Lymphoblastic Leukemia and Its Involvement in Leukemic Relapse.

Authors:  Lobna Ben Mahmoud; Moez Mdhaffar; Hanene Ghozzi; Mariam Ammar; Ahmed Hakim; Rim Atheymen; Zouheir Sahnoun; Moez Elloumi; Khaled Zeghal
Journal:  J Pediatr Hematol Oncol       Date:  2017-04       Impact factor: 1.289

6.  Expression of CD133 in acute leukemia.

Authors:  Fetnat M Tolba; Mona E Foda; Howyda M Kamal; Deena A Elshabrawy
Journal:  Med Oncol       Date:  2013-03-27       Impact factor: 3.064

7.  mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia.

Authors:  David T Teachey; Cecilia Sheen; Junior Hall; Theresa Ryan; Valerie I Brown; Jonathan Fish; Gregor S D Reid; Alix E Seif; Robin Norris; Yueh J Chang; Martin Carroll; Stephan A Grupp
Journal:  Blood       Date:  2008-06-10       Impact factor: 22.113

Review 8.  Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies.

Authors:  David T Teachey; Stephan A Grupp; Valerie I Brown
Journal:  Br J Haematol       Date:  2009-03-16       Impact factor: 6.998

9.  What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies.

Authors:  Wendy Stock; Mei La; Ben Sanford; Clara D Bloomfield; James W Vardiman; Paul Gaynon; Richard A Larson; James Nachman
Journal:  Blood       Date:  2008-05-23       Impact factor: 22.113

10.  Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group.

Authors:  James B Nachman; Mei K La; Stephen P Hunger; Nyla A Heerema; Paul S Gaynon; Caroline Hastings; Leonard A Mattano; Harland Sather; Meenakshi Devidas; David R Freyer; Peter G Steinherz; Nita L Seibel
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.